Programmed cell death 1 receptor

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Todd M Bauer, Armando Santoro, Chia-Chi Lin, Ignacio Garrido-Laguna, Markus Joerger, Richard Greil, Anna Spreafico, Thomas Yau, Maria-Elisabeth Goebeler, Marie Luise Hütter-Krönke, Antonella Perotti, Pierre-Eric Juif, Darlene Lu, Louise Barys, Viviana Cremasco, Marc Pelletier, Helen Evans, Claire Fabre, Toshikiko Doi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007353; DOI: 10.1136/jitc-2023-007353
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Aanika Balaji, Melinda Hsu, Cheng Ting Lin, Josephine Feliciano, Kristen Marrone, Julie R Brahmer, Patrick M Forde, Christine Hann, Lei Zheng, Valerie Lee, Peter B Illei, Sonye K Danoff, Karthik Suresh, Jarushka Naidoo

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e001731; DOI: 10.1136/jitc-2020-001731
Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8⁺ T cell antitumor immunity
Anqi Li, Yuzhou Chang, No-Joon Song, Xingjun Wu, Dongjun Chung, Brian P Riesenberg, Maria Velegraki, Giuseppe D Giuliani, Komal Das, Tamio Okimoto, Hyunwoo Kwon, Karthik B Chakravarthy, Chelsea Bolyard, Yi Wang, Kai He, Margaret Gatti-Mays, Jayajit Das, Yiping Yang, Daniel T Gewirth, Qin Ma, David Carbone, Zihai Li

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005433; DOI: 10.1136/jitc-2022-005433
FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
Jiaxin Liu, Lingyun Wei, Nan Hu, Dong Wang, Juan Ni, Sha Zhang, Hongbing Liu, Tangfeng Lv, Jie Yin, Mingxiang Ye, Yong Song

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005116; DOI: 10.1136/jitc-2022-005116
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
Amelie Franken, Pierre Van Mol, Sam Vanmassenhove, Elena Donders, Rogier Schepers, Thomas Van Brussel, Christophe Dooms, Jonas Yserbyt, Nico De Crem, Dries Testelmans, Walter De Wever, Kristiaan Nackaerts, Johan Vansteenkiste, Robin Vos, Stéphanie Humblet-Baron, Diether Lambrechts, Els Wauters

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005323; DOI: 10.1136/jitc-2022-005323
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
Rikke Boedker Holmstroem, Ole Haagen Nielsen, Søren Jacobsen, Lene Buhl Riis, Susann Theile, Jacob Tveiten Bjerrum, Peter Vilmann, Julia Sidenius Johansen, Mogens Karsbøl Boisen, Rikke Helene Løvendahl Eefsen, Inge Marie Svane, Dorte Lisbet Nielsen, Inna Markovna Chen

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005111; DOI: 10.1136/jitc-2022-005111
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
Rick D Vavolizza, Gina R Petroni, Ileana S Mauldin, Kimberly A Chianese-Bullock, Walter C Olson, Kelly T Smith, Lynn T Dengel, Kathleen Haden, William W Grosh, Varinder Kaur, Nikole Varhegyi, Elizabeth M Gaughan, Craig L Slingluff

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005424; DOI: 10.1136/jitc-2022-005424
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Danny Rischin, Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf, Samantha Bowyer, Sabiha Trabelsi Messai, Friedegund Meier, Thomas K Eigentler, Victoria Casado Echarren, Brian Stein, Marie Beylot-Barry, Sophie Dalac, Brigitte Dréno, Michael R Migden, Axel Hauschild, Chrysalyne D Schmults, Annette M Lim, Suk-Young Yoo, Anne J Paccaly, Apostolos Papachristos, Jenny-Hoa Nguyen, Emmanuel Okoye, Frank Seebach, Jocelyn Booth, Israel Lowy, Matthew G Fury, Alexander Guminski

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008325; DOI: 10.1136/jitc-2023-008325
Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer
Yun Zhou, Wenyao Zhang, Boda Wang, Pei Wang, Danxiu Li, Tianyu Cao, Dawei Zhang, Hua Han, Mingfeng Bai, Xin Wang, Xiaodi Zhao, Yuanyuan Lu

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008054; DOI: 10.1136/jitc-2023-008054
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
Pengfei Xu, Joy C Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P Evans, William J Murphy, Chengfei Liu

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006581; DOI: 10.1136/jitc-2022-006581

Main menu

Programmed cell death 1 receptor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Programmed cell death 1 receptor

Pages